Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis

Pediatric Critical Care Medicine

Volumn 12, Issue 5, 2011, Pages 580-588

  Checchia, Paul A ^a   Nalysnyk, Luba ^b   Fernandes, Ancilla W ^c   Mahadevia, Parthiv J ^c   Xu, Yingxin ^b   Fahrbach, Kyle ^b   Welliver Sr , Robert C ^d  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c MEDIMMUNE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

High risk; Hospitalization; Infants; Infectious disease; Mortality; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ALLERGIC RHINITIS; ANTIVIRAL THERAPY; APNEA; ASSISTED VENTILATION; ASTHMA; ATOPY; BIRTH WEIGHT; CHEMOPROPHYLAXIS; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; ECZEMA; EMBASE; EVALUATION; FAMILY HISTORY; GESTATIONAL AGE; HAY FEVER; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; INFANT; MEDLINE; META ANALYSIS; MORBIDITY; MORTALITY; OXYGEN THERAPY; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW;

EID: 80455127363     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3182070990     Document Type: Review

References (38)

1. Simoes EA: Respiratory syncytial virus infection. Lancet 1999; 354:847-852 (Pubitemid 29415599)
2. Forbes ML, Hall CB, Jackson A, et al: Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life. J Med Econ 2010; 13: 136-141
3. American Academy of Pediatrics: Respiratory Syncytial Virus. In: Red Book: 2006 Report of the Committee on Infectious Diseases. 27th Edition. Pickering LK, Baker CJ, Long SS, et al (Eds). Elk Grove Village, IL, American Academy of Pediatrics, 2006, pp 560-566
4. The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in infants at high risk. Pediatrics 1998; 102:531-537
5. Shay DK, Holman RC, Newman RD, et al: Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282:1440-1446
6. Law BJ: The issue of RSV in premature infants. Presented at the 18th Annual Meeting of the European Society for Paediatric Infectious Diseases, May 3-5, 2000, Noordwijk, The Netherlands
7. Hay JW, Ernst RL, Meissner HC: Respiratory syncytial virus immune globulin: A costeffectiveness analysis. Am J Manag Care 1996; 2:851-861
8. Howard TS, Hoffman LH, Stang PE, et al: Respiratory syncytial virus pneumonia in the hospital setting: Length of stay, charges, and mortality. J Pediatr 2000; 137:227-232 (Pubitemid 30659231)
9. Numa A: Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health 2000; 36:422-427
10. Prober CG, Sullender WM: Advances in prevention of respiratory syncytial virus infections. J Pediatr 1999; 135:546-558 (Pubitemid 30180443)
11. Shay DK, Holman RC, Roosevelt GE, et al: Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001; 183:16-22 (Pubitemid 32043037)
12. Leader S, Kohlhase K: Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003; 143:S127-S132 (Pubitemid 37456910)
13. Thompson WW, Shay DK, Weintraub E, et al: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-186 (Pubitemid 36068705)
14. Feltes TF, Cabalka AK, Meissner HC, et al: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-540 (Pubitemid 37352516)
15. Centre for Evidence Based Medicine: Oxford Centre for Evidence-based Medicine-Levels of evidence (March 2009). Available at: http://www.cebm.net/ index.aspx?o-1025. Accessed December 31, 2010
16. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17:1-12 (Pubitemid 26120810)
17. Yusuf S, Peto R, Lewis J, et al: Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335-371 (Pubitemid 15107153)
18. Lacaze-Masmonteil T, Truffert P, Pinquier D, et al: Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch Dis Child 2004; 89:562-567
19. Grimaldi M, Gouyon B, Michaut F, et al: Severe respiratory syncytial virus bronchiolitis: Epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 2004; 23: 1081-1085 (Pubitemid 40812752)
20. Henckel E, Luthander J, Berggren E, et al: Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Pediatr Infect Dis J 2004; 23:27-31 (Pubitemid 38176757)
21. Kusuda S, Koizumi T, Sakai T, et al: Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003. Pediatr Int 2006; 48:362-368
22. Mitchell I, Tough S, Gillis L, et al: Beyond randomized controlled trials: A "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 2006; 41: 1167-1174 (Pubitemid 44893870)
23. Pedraz C, Carbonell-Estrany X, Figueras- Aloy J, et al: Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003; 22:823-827 (Pubitemid 37153079)
24. Perez Perez G, Navarro Merino M, Romero Perez MM, et al: [Respiratory morbidity after hospital discharge in premature infants born at- or ≤ 32 weeks gestation with bronchopulmonary dysplasia]. An Pediatr (Barc) 2004; 60:117-124 (Pubitemid 38418571)
25. Subramanian KN, Weisman LE, Rhodes T, et al: Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17:110-115 (Pubitemid 28096007)
26. Wegner S, Vann JJ, Liu G, et al: Direct cost analyses of palivizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program. Pediatrics 2004; 114:1612-1619 (Pubitemid 41754927)
27. Centers for Disease Control and Prevention National Center for Health Statistics: Data file documentations, linked birth/infant death period public-use files, 1998 -2003 (machine readable data file and documentation, CD-ROM series). National Center for Health Statistics. Available at: http://www.cdc. gov/nchs/. December 31, 2010
28. Institute of Medicine: To err is human: Building a safer health system. Kohn LT, Corrigan JM, Molla S, et al (Eds). Washington, DC, National Academy Press, 2000
29. Thorburn K: Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009; 94:99-103
30. Kendirli T, Kavaz A, Yalaki Z, et al: Mechanical ventilation in children. Turk J Pediatr 2006; 48:323-327 (Pubitemid 46062231)
31. Elward AM, Warren DK, Fraser VJ: Ventilator- associated pneumonia in pediatric intensive care unit patients: risk factors and outcomes. Pediatrics 2002; 109:758-764 (Pubitemid 34493339)
32. Frogel M, Nerwen C, Cohen A, et al: Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28: 511-517 (Pubitemid 351973995)
33. West S, King V, Carey TS, et al: Systems to rate the strength of scientific evidence. Evid Rep Technol Assess (Summ) 2002; 47:1-11
34. Carbonell Estrany X, Quero Jiménez J: [Recommendations for the prevention of respiratory syncytial virus infections. Standards Committee of the Spanish Society of Neonatology. Board of Directors of the Spanish Society of Neonatology]. An Esp Pediatr 2000; 52:372-374 (Pubitemid 32385489)
35. Nishida H, Fujimura M, Takeuchi Y, et al: Prevention of RS virus infection (the guidelines for use of palivizumab in Japan). J Jp Pediatr Soc 2002; 106:1288-1292
36. Tulloh R, Marsh M, Blackburn M, et al: Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003; 13: 420-423 (Pubitemid 41630963)
37. Tulloh RM, Feltes TF: The European Forum for Clinical Management: Prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease. Cardiol Young 2005; 15: 274-278 (Pubitemid 41388054)
38. Weigl JA, Puppe W, Belke O, et al: The descriptive epidemiology of severe lower respiratory tract infections in children in Kiel, Germany. Klin Padiatr 2005; 217: 259-267 (Pubitemid 41391938)